Preston, Nancy (1996) Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent). European Journal of Cancer Care, 5 (3). pp. 147-152.Full text not available from this repository.
The introduction of a new chemotherapeutic agent has implications for nursing care. Paclitaxel (Taxol®) chemotherapy is now being used throughout Europe for treatment of patients with ovarian cancer who have previously failed a platinum-containing chemotherapy regimen, and in many countries to treat metastatic breast cancer. Nurses need to be equipped to care for these patients receiving Paclitaxel. This paper introduces nurses to Paclitaxel, the history of its development, its mechanism of action, potential side-effects and administration. Paclitaxel's side-effects include hypersensitivity reactions, neutropaenia, peripheral neuropathy, asymptomatic bradycardia, alopecia, malaise, myalgias and arthralgias. Administration guidelines will be discussed because Paclitaxel leaches plasticizer from polyvinyl chloride (PVC) intravenous-giving sets normally used to administer chemotherapy, hence an alternative delivery system is required.
|Journal or Publication Title:||European Journal of Cancer Care|
|Subjects:||R Medicine > R Medicine (General)|
|Departments:||Faculty of Health and Medicine > Health Research|
|Deposited By:||Mrs Yaling Zhang|
|Deposited On:||25 Mar 2010 10:08|
|Last Modified:||07 Jan 2015 14:31|
Actions (login required)